{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:35:26Z","timestamp":1782218126834,"version":"3.54.5"},"reference-count":24,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Premix insulin is commonly used in some regions of the world, despite the higher risk of hypoglycaemia and weight gain compared with basal insulin, based on the premise that it offers a simplified insulin regimen. iGlarLixi is a once\u2010daily titratable fixed\u2010ratio formulation that combines basal insulin glargine 100 units\/mL (iGlar) and the GLP\u20101 RA, lixisenatide, which offers a single\u2010injection option for treatment intensification, with improved HbA1c reductions, similar hypoglycaemia risk and more favourable bodyweight profiles over iGlar alone. This randomized controlled study directly compares, for the first time, treatment intensification with iGlarLixi versus premix insulin analogue biphasic insulin aspart 30 (BIAsp 30) in adults with T2D inadequately controlled on basal insulin in combination with one or two oral antihyperglycaemic drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This was an open\u2010label, active\u2010controlled, comparative, parallel\u2010group, multicentre, phase 3b study. In total, 887 adults with T2D uncontrolled on basal insulin were randomized to switch to either iGlarLixi once daily, or BIAsp 30 twice daily, for 26\u2009weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 887 participants were enrolled (mean age 59.8\u2009years, 50.2% female) from 89 centres in 17 countries. At baseline, 65.6% had a duration of T2D of 10\u2009years or longer, and the mean HbA1c at baseline was 8.6%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The study directly compared the efficacy and safety of iGlarLixi versus BIAsp 30 in people with T2D uncontrolled on basal insulin and one or more oral antihyperglycaemic agents. These results provide robust clinical data that may inform clinicians in their therapeutic management of people with T2D uncontrolled on basal insulin requiring additional therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.14354","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T12:30:53Z","timestamp":1613737853000},"page":"1221-1231","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Advancing therapy with\n                    <scp>iGlarLixi<\/scp>\n                    versus premix BIAsp 30 in basal insulin\u2010treated type 2 diabetes: Design and baseline characteristics of the\n                    <scp>SoliMix<\/scp>\n                    randomized controlled trial"],"prefix":"10.1111","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3957-1981","authenticated-orcid":false,"given":"Rory J.","family":"McCrimmon","sequence":"first","affiliation":[{"name":"Division of Systems Medicine, School of Medicine University of Dundee  Dundee UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saud","family":"Al Sifri","sequence":"additional","affiliation":[{"name":"Al Hada Military Hospital  Taif Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifat","family":"Emral","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolic Diseases Ankara University Faculty of Medicine  Ankara Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5038-6210","authenticated-orcid":false,"given":"Viswanathan","family":"Mohan","sequence":"additional","affiliation":[{"name":"Dr. Mohan's Diabetes Specialities Centre &amp; Madras Diabetes Research Foundation, IDF Centre of Excellence in Diabetes Care &amp; ICMR Centre for Advanced Research on Diabetes  Chennai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leobardo","family":"Sauque\u2010Reyna","sequence":"additional","affiliation":[{"name":"Instituto de Diabetes Obesidad y Nutrici\u00f3n S.C.  Cuernavaca Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Trescol\u00ed","sequence":"additional","affiliation":[{"name":"Hospital Universitario de La Ribera  Alzira Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nebojsa","family":"Lalic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine of the University of Belgrade, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia  Belgrade Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustina","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Sanofi  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nacima","family":"Demil","sequence":"additional","affiliation":[{"name":"Diabetes Medical Operation Department Sanofi  Chilly\u2010Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Coudert","sequence":"additional","affiliation":[{"name":"Biostatistics and Programming Department Sanofi  Chilly\u2010Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alka","family":"Shaunik","sequence":"additional","affiliation":[{"name":"Sanofi US  Bridgewater New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"Bonnemaire","sequence":"additional","affiliation":[{"name":"Sanofi  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8324-3275","authenticated-orcid":false,"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[{"name":"Dallas Diabetes Research Center at Medical City  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"SoliMix Trial investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S006"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S009"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0331"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2016.1157462"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13132"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12927"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13673"},{"key":"e_1_2_9_10_1","unstructured":"Sanofi. Soliqua\u00ae: US prescribing information.2020. https:\/\/products.sanofi.us\/Soliqua100\u201033\/Soliqua100\u201033.pdf. Accessed January 4 2021."},{"key":"e_1_2_9_11_1","unstructured":"Sanofi. Suliqua\u00ae: EU summary of product characteristics.2019.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/suliqua. Accessed January 23 2020."},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108478"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1495"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1357"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0917"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14148"},{"key":"e_1_2_9_17_1","unstructured":"Food and Drug Administration.Non\u2010inferiority clinical trials to establish effectiveness \u2013 guidance for industry.2016; https:\/\/www.fda.gov\/media\/78504\/download. Accessed 13 October."},{"key":"e_1_2_9_18_1","unstructured":"Novo Nordisk Limited.NovoMix 30 Penfill 100 units\/ml NovoMix 30 FlexPen 100 units\/ml.2020. https:\/\/www.medicines.org.uk\/emc\/product\/1600\/smpc. Accessed October 22 2020."},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14298"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.07.003"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2014.170"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2215"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13064"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/db10-0103"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S106821"}],"updated-by":[{"DOI":"10.1111\/dom.14531","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000}}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14354","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14354","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:29:02Z","timestamp":1761874142000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1111\/dom.14354"],"URL":"https:\/\/doi.org\/10.1111\/dom.14354","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.14354\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14354\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14354\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14354\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14354\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14354\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14354\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14354\/v1\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]},"assertion":[{"value":"2020-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}